Link Between Lipid Profile, eCBome System and Gut Microbiota in Fragile X Syndrome

Link Between Lipid Profile, eCBome System and Gut Microbiota in Fragile X Syndrome

Artuela Çaku, MD
Principal Investigator

Armita Abolghasemi, PhD
Co-Principal Investigator

Université de Sherbrooke
Quebec, Canada

2021 Grant Funding: $90,000

University Total Funding: $250,714

Summary

Why does obesity challenge so many people with Fragile X? Dr. Caku’s team thinks changes in the gut are the culprit.

This team has found that Fragile X syndrome causes changes in the tiny organisms that live in our gut. They believe that these abnormalities cause changes in the brain which impair learning and behavior.

With this grant, the researchers will test individuals with Fragile X. If they find the changes they expect to see, then treatments like probiotics or fatty acids might be effective in treating not just obesity, but a whole range of Fragile X symptoms.

The Science

By Artuela Çaku

Fragile X syndrome (FXS) is a genetic disorder characterized by mild-to-moderate intellectual disability. Many FXS patients have shown to be overweight or obese, while blood cholesterol levels are unexpectedly low. This abnormality suggests a dysregulation of lipid metabolism in FXS. Other factors may affect lipid metabolism such as the endocannabinoidome system and the gut microbiota. The endocannabinoidome system is a biological system composed of lipid derivative molecules while gut microbiota includes bacteria, fungi and other types of microorganism which live in humans’ and animals’ digestive tracts. Each of these systems (endocannabinoidome and gut microbiota), individually and/or linked together affect lipid metabolism and have been studied in many cognitive diseases.

In this project, we are going to study lipids, endocannabinoidome and gut microbiota in FXS children and adults compare to controls. We believe that dysregulation in each or all of these systems may influence functional behaviors in FXS individuals. Discovering the changes that happen in lipids, endocannabinoidome, and gut microbiota in FXS may lead to next clinical studies that will test novel treatment.

Global Leader in Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Explore Current Research Grants
Help Fund the Cure

Global Leader in Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.

Explore Current Research Grants
Help Fund the Cure

Share via
Copy link